46.3 Acute Urinary Retention & Incontinence Evaluation

Etiology & Pathophysiology of Acute Urinary Retention (AUR)

Acute urinary retention (AUR) is defined as the sudden, painful inability to voluntarily void urine, resulting in acute, tense overdistension of the urinary bladder. AUR is the most common urologic emergency in adult men, with an annual incidence of approximately 3 cases per 1,000 person-years, rising dramatically in men aged >=70 years.

Mechanistic Classification

The pathophysiologic mechanisms underlying acute urinary retention fall into three broad categories:

1. Outflow Obstruction (Mechanical Obstruction):
   • Benign Prostatic Hyperplasia (BPH): The single leading cause of AUR (>70% of cases), resulting from nodular adenomatous hyperplasia of the transition zone surrounding the proximal urethra.
   • Prostate adenocarcinoma, urethral stricture disease, bladder calculi, meatal stenosis, severe phimosis, and pelvic or retroperitoneal malignancies.
   • Severe Constipation and Fecal Impaction: Massive hard stool in the rectal vault mechanically compresses the posterior bladder neck and urethra, while stimulating rectal mechanoreceptors that reflexively inhibit detrusor contraction.
2. Neurogenic & Detrusor Contractility Failure:
   • Acute spinal cord compression, Cauda Equina Syndrome (characterized by saddle anesthesia, lax anal sphincter tone, and bilateral lower extremity weakness; AUR with overflow incontinence carries >90% sensitivity for CES).
   • Diabetic autonomic neuropathy (diabetic cystopathy causing sensory denervation and atonic detrusor failure), acute stroke, tabes dorsalis, and multiple sclerosis.
3. Pharmacologic Precipitation:
   • Drug-induced urinary retention is responsible for up to 30% of all acute presentations in older adults.

               HIGH-RISK DRUG CLASSES PRECIPITATING URINARY RETENTION

   Medication Class        Specific Common Agents             Mechanism Inducing Retention
   ═════════════════════════════════════════════════════════════════════════════════════════════
   Anticholinergics /      Diphenhydramine, Hydroxyzine,      Block muscarinic M3 receptors on the
   First-Gen Antihistamines Chlorpheniramine, Meclizine       detrusor muscle, abolishing bladder
                                                              contractile force.

   Bladder Antispasmodics  Oxybutynin, Tolterodine,           Potent competitive M2/M3 receptor
                           Solifenacin, Darifenacin           antagonism; suppresses detrusor activity.

   Tricyclic               Amitriptyline, Nortriptyline,      Potent anticholinergic antagonism
   Antidepressants (TCAs)  Imipramine, Doxepin                combined with central sedation.

   Sympathomimetics /      Pseudoephedrine, Ephedrine,        Stimulate alpha-1 adrenergic receptors
   Oral Decongestants      Phenylephrine                      at the bladder neck and prostatic
                                                              capsule, markedly increasing outflow resistance.

   Opioid Analgesics       Morphine, Oxycodone, Hydrocodone,  Inhibit central sacral micturition pathways,
                           Fentanyl, Hydromorphone            decrease bladder sensation, and relax detrusor.

   Anesthetic Agents /     Spinal anesthesia, epidural,       Bladder sensory stunning, hyperhydration,
   Postoperative State     high-dose IV sedatives             and pain-mediated sympathetic tone.
   ═════════════════════════════════════════════════════════════════════════════════════════════

Clinical Presentation & Emergency Bladder Decompression

Clinical Presentation

• Symptoms: Agonizing, severe lower abdominal and suprapubic pain, accompanied by an intense, relentless urge to urinate but complete inability to void. Patients appear acutely distressed, restless, diaphoretic, and hypertensive from profound autonomic sympathetic stimulation.
• Physical Examination:
  • Palpation and percussion of the lower abdomen reveals a tense, smooth, tender, globe-like suprapubic mass arising out of the pelvis, which is dull to percussion.
  • Digital rectal examination evaluates prostate volume, contour, symmetry, and tenderness, while confirming the presence or absence of fecal impaction.
  • Focused neurological examination must assess bilateral lower extremity motor strength, patellar and Achilles reflexes, perineal sensation (S2-S5 dermatomes), and resting/voluntary anal sphincter tone to rule out cauda equina compression.
• Diagnostic Confirmation:
  • Bedside bladder ultrasonography or formal post-void residual (PVR) measurement: A documented urine volume >300 to 500 mL in a patient who cannot void establishes the diagnosis of AUR.

Catheter Decompression Technique & The Coudé Tip Catheter

Immediate bladder decompression is the primary therapeutic priority. Decompression relieves excruciating suffering, terminates sympathetic overdrive, and prevents permanent myogenic detrusor damage.

• Standard Urethral Catheterization:
  • Cleanse the glans penis and instill 10 to 20 mL of sterile 2% lidocaine jelly into the urethra using a prefilled syringe, holding the meatus closed for 5 to 10 minutes to achieve topical anesthesia and gentle hydrodistension.
  • Insert a standard 14 to 16 French soft silicone or latex Foley catheter with gentle continuous traction on the penis at a 90° angle toward the ceiling (straightening the anterior urethra).
• The Difficult Catheterization & The Coudé Catheter:
  • If the catheter meets firm, rubbery resistance at 15 to 20 cm from the meatus, the catheter has reached the prostatic urethra and bladder neck.
  • CLINICAL MANDATE: Never use forceful pressure against resistance! Forcing a standard straight-tip catheter risks creating a traumatic mucosal false passage, deep urethral laceration, massive hemorrhage, or bladder neck perforation.
  • The Coudé Tip Catheter:
    • A specialized catheter with a firm, angled, upward-curved (elbowed) beak.
    • The curved tip is designed specifically to ride anteriorly over an enlarged, hypertrophied median prostatic lobe or elevated bladder neck.
    • Proper Technique: Insert the Coudé catheter with the curved tip pointing strictly upward toward the ceiling / patient's umbilicus (12 o'clock position). Most Coudé catheters have a raised indicator ridge on the drainage funnel indicating the direction of the curved beak.
• Failed Transurethral Catheterization:
  • If two attempts with a Coudé catheter fail, do not make repeated blind attempts. Immediately consult urology for flexible cystoscopy-guided wire placement or emergent percutaneous suprapubic cystostomy.

Post-Obstructive Diuresis (POD): Monitoring & Management

Following rapid decompression of severe or long-standing urinary tract obstruction, patients can develop a dangerous, life-threatening polyuric syndrome known as Post-Obstructive Diuresis (POD).

Pathophysiological Mechanism

Post-obstructive diuresis is defined as a sustained urine output of >200 mL/hour for >=2 consecutive hours, or >3,000 to 4,000 mL in 24 hours following relief of obstruction. The mechanisms include:

1. Osmotic Diuresis: Rapid excretion of high concentrations of accumulated urea, creatinine, and unabsorbed osmoles that were retained during the obstructive episode, dragging water osmotically into the tubular lumen.
2. Loss of Medullary Hypertonicity: Long-standing elevated retrograde intrarenal pressures wash out the hypertonic medullary solute gradient (medullary washout), impairing the countercurrent multiplier mechanism.
3. Tubular Unresponsiveness: Ischemic injury to renal medullary collecting ducts produces transient tubular insensitivity to antidiuretic hormone (nephrogenic diabetes insipidus-like state) and downregulates sodium-potassium ATPase pumps, provoking profound natriuresis.

Clinical Monitoring Protocol

Not all post-catheterization polyuria is pathological. In many patients, polyuria is simply a physiologic diuresis eliminating excess extracellular fluid retained during renal compromise. Clinicians must differentiate physiologic volume shedding from pathologic salt-wasting diuresis:

                 POST-OBSTRUCTIVE DIURESIS PROTOCOL

   Clinical Parameter     Monitoring Frequency           Intervention Threshold
   ═════════════════════════════════════════════════════════════════════════════════════════════
   Urine Volume           Strict hourly measurement via  > 200 mL/hr for 2 consecutive hours
                          graduated urometer bag         activates close monitoring protocol.

   Hemodynamics & Vitals  Hourly blood pressure, pulse,  Drop in SBP, tachycardia, or orthostasis
                          and postural signs             indicates intravascular volume depletion.

   Electrolytes & Renal   Serum BUN, Creatinine, Na, K,  Check every 6 to 12 hours; monitor for
   Function Panels        Bicarbonate, Mg, Phosphorus    severe hypokalemia, hyponatremia, uremia.

   Fluid Balance & Weight Daily weights; strict 24-hour  Guides net fluid balance and reveals
                          intake and output totals       unrecognized fluid contraction.
   ═════════════════════════════════════════════════════════════════════════════════════════════

Fluid Replacement Strategy: The 50% Rule

• Alert, Hemodynamically Stable Patients: If the patient is awake, alert, possesses normal thirst mechanisms, maintains stable vital signs, and has access to oral fluids, routine intravenous fluid replacement is NOT necessary. Over-treating with IV fluids is the single most common clinical error: administering rapid IV fluids perpetuates a continuous, iatrogenic polyuric state by continuously infusing volume that the kidneys must clear!
• Hemodynamically Unstable or Pathologic Salt-Wasting Diuresis:
  • Indicated if the patient exhibits postural hypotension, tachycardia, altered mental status, severe electrolyte depletion (hypokalemia, hyponatremia), or cannot drink.
  • The 0.5x Replacement Rule: Administer intravenous 0.45% normal saline (half-normal saline, with potassium chloride supplementation as indicated by serum levels) replacing 0.5 times (50%) of the preceding hour's urine output: $\text{IV Infusion Rate (mL/hr)} = 0.5 \times \text{Urine Output in Preceding Hour (mL)}$
  • This replacement rate maintains adequate effective circulating arterial volume without driving an endless cycle of iatrogenic volume-overload polyuria.

Outpatient BPH Management After Retention: The TWOC Protocol

When acute urinary retention is precipitated by benign prostatic hyperplasia, the clinical objective is to transition the patient from indwelling catheter dependence to successful spontaneous voiding.

The Trial Without Catheter (TWOC) Protocol

1. Immediate Pharmacotherapy: Initiate an oral selective alpha-1 adrenergic receptor antagonist (e.g., Tamsulosin 0.4 mg PO daily or Alfuzosin 10 mg PO daily) on the very day of catheter placement.
2. Duration of Catheterization: Maintain continuous indwelling catheter drainage for 3 to 7 days. A minimum of 3 days allows time for the overdistended, micro-teared detrusor muscle to recover baseline contractile tone, for acute intraprostatic edema to subside, and for the alpha-blocker to achieve steady-state therapeutic levels.
3. Conducting the TWOC:
   • The patient presents to the clinic early in the morning.
   • Remove the Foley catheter and encourage normal oral hydration.
   • Observe the patient for spontaneous voiding over the subsequent 4 to 6 hours.
   • Following spontaneous urination, measure the post-void residual (PVR) via ultrasound.
4. TWOC Outcomes:
   • Successful TWOC: Patient voids spontaneously with adequate volumes and a PVR <150 to 200 mL without abdominal discomfort. The patient continues the alpha-blocker long-term with routine outpatient follow-up.
   • Failed TWOC: Patient is unable to void within 4 to 6 hours, experiences severe painful distension, or demonstrates a persistently elevated PVR (>200 to 300 mL). Re-insert a Foley catheter immediately and refer to urology for definitive surgical consideration.

• The Evidence: Landmark randomized clinical trials prove that initiating an alpha-blocker prior to TWOC doubles the rate of successful voiding (60% to 70% success with alpha-blocker vs 25% to 35% with placebo) and significantly reduces early recurrence of AUR.

Long-Term Pharmacotherapy of Benign Prostatic Hyperplasia (BPH)

Benign prostatic hyperplasia is characterized by progressive non-malignant adenomatous proliferation of the prostatic glandular and stromal elements, causing bladder outlet obstruction.

                  COMPARATIVE PHARMACOLOGY OF BPH MEDICATIONS

   Drug Class & Agents     Mechanism of Action            Clinical Impact & Onset         Adverse Effects & Pearls
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════
   Alpha-1 Adrenergic      Block alpha-1A receptors in    • RAPID onset (within 3-7 days) • Dizziness, headache
   Antagonists             prostate stroma, capsule,      • Improves IPSS by 4-6 points   • Orthostatic hypotension
   • Tamsulosin 0.4 mg     and bladder neck; relaxes      • Increases Qmax by 2-3 mL/s    • Retrograde ejaculation
   • Alfuzosin 10 mg       smooth muscle to decrease      • Does NOT shrink prostate      • Intraoperative Floppy
   • Silodosin 8 mg        dynamic outflow resistance.    • Does NOT prevent AUR/surgery    Iris Syndrome (IFIS)

   5-Alpha-Reductase       Inhibit conversion of          • SLOW onset (requires 6-12 mo) • Decreased libido, ED
   Inhibitors (5-ARIs)     testosterone to DHT; induces   • SHRINKS prostate by 20-30%    • Ejaculatory dysfunction
   • Finasteride 5 mg      epithelial apoptosis.          • Halts disease progression     • Gynecomastia
   • Dutasteride 0.5 mg    Targeted for enlarged glands   • Reduces AUR risk by ~57%      • SUPPRESSES SERUM PSA
                           (volume > 30-40 mL).           • Reduces surgery risk by ~55%    BY 50% (Must double PSA)

   Combination Therapy     Synergistic dynamic relaxation • Superior to either monotherapy• Summation of individual
   • Tamsulosin PLUS       combined with progressive      • Validated by MTOPS & CombAT   adverse effect profiles
     Dutasteride/Finasteride anatomic volume reduction.     trials for high-risk BPH

   PDE-5 Inhibitors        Increase intracellular cGMP;   • Rapid relief of mild-moderate • Headache, flushing, dyspepsia
   • Tadalafil 5 mg daily  relaxes detrusor, prostate,    LUTS with concurrent ED         • Contraindicated with nitrates
                           and pelvic vasculature.        • No effect on prostate size
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════

Clinical Pearls: Alpha-Blockers & IFIS

• Intraoperative Floppy Iris Syndrome (IFIS):
  • Alpha-1 adrenergic receptors are located in the iris dilator muscle. Systemic alpha-1 blockers (particularly tamsulosin, due to its high alpha-1A selectivity) cause permanent or long-lasting loss of iris muscle tone.
  • During cataract extraction surgery, patients taking (or who have previously taken) alpha-blockers can develop a classic triad: billowing of a flaccid iris stroma, progressive intraoperative pupillary miosis, and prolapse of the iris toward the phacoemulsification incision.
  • Clinical Mandate: Primary care physicians must ask patients about upcoming cataract surgery prior to starting alpha-blockers, and advise patients to explicitly inform their ophthalmologist so that mechanical iris retractors or intraoperative intracameral phenylephrine can be utilized.

Clinical Pearls: 5-ARIs & The PSA-Doubling Rule

[!IMPORTANT] THE 5-ALPHA-REDUCTASE INHIBITOR PSA-DOUBLING MANDATE Treatment with a 5-alpha-reductase inhibitor (Finasteride 5 mg daily or Dutasteride 0.5 mg daily) suppresses serum Prostate-Specific Antigen (PSA) by approximately 50% after 6 months of continuous therapy.

To evaluate serum PSA accurately for prostate cancer screening in a patient who has taken a 5-ARI for >=6 months, the clinician MUST MULTIPLY THE MEASURED SERUM PSA VALUE BY 2 (DOUBLE THE VALUE) to compare it to historical baselines and normal population thresholds. Any confirmed rise in serum PSA while a patient is compliant on a 5-ARI is abnormal and warrants immediate urologic referral for prostate cancer evaluation.

Diagnostic Evaluation & Classification of Urinary Incontinence

Urinary incontinence is the involuntary loss of urine, representing a major clinical and quality-of-life issue affecting over 50% of community-dwelling older women and up to 15% of older men.

Initial Evaluation & Reversible Causes: The DIAPPERS Mnemonic

Before diagnosing primary bladder dysfunction, primary care physicians must screen for transient, reversible precipitants using the validated DIAPPERS framework:

• D — Delirium / Acute confusional state
• I — Infection (Symptomatic urinary tract infection)
• A — Atrophic vaginitis / Atrophic urethritis (hypoestrogenism)
• P — Pharmaceuticals (Diuretics, anticholinergics, alpha-blockers, sedatives)
• P — Psychological disorders (Severe depression)
• E — Excessive urine output (Uncontrolled diabetes mellitus with glucosuria, hypercalcemia, congestive heart failure with dependent edema)
• R — Restricted mobility (Severe osteoarthritis, contractures, environmental barriers)
• S — Stool impaction / Severe constipation

                  SYSTEMATIC CLASSIFICATION OF URINARY INCONTINENCE

   Incontinence Type       Pathophysiologic Mechanism           Clinical Hallmark               Post-Void Residual
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════
   Stress Urinary          Urethral hypermobility (pelvic floor Involuntary leakage with        NORMAL
   Incontinence (SUI)      laxity) OR intrinsic sphincter       coughing, sneezing, laughing,   (PVR < 50 mL)
                           deficiency. Intravesical pressure    jumping, or lifting. No urge.
                           exceeds urethral closure pressure.

   Urgency Urinary         Detrusor muscle overactivity         Sudden, compelling urge to      NORMAL
   Incontinence (UUI) /    (involuntary detrusor contractions   urinate followed immediately by (PVR < 50-100 mL)
   Overactive Bladder      during filling phase).               uncontrolled large-volume leakage.

   Overflow Urinary        Impaired detrusor contractility      Constant or intermittent        ELEVATED
   Incontinence            (neurogenic / myogenic) OR severe    involuntary dribbling, weak     (PVR > 200-300 mL)
                           bladder outlet obstruction.          stream, incomplete emptying.

   Functional              Intact bladder mechanics; physical,  Inability to reach toilet in    NORMAL
   Incontinence            cognitive, or environmental barriers time due to arthritis, dementia,
                           prevent timely toilet access.        sedation, or physical restraints.
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════

Evidence-Based Management by Incontinence Subtype

1. Stress Urinary Incontinence (SUI)

• First-Line Conservative Therapy: Structured Pelvic Floor Muscle Training (PFMT / Kegel exercises), supervised by a physical therapist. Prescribe 3 sets of 10 to 15 sustained contractions (held for 6 to 8 seconds) daily for at least 12 weeks. Biofeedback and vaginal weighted cones enhance compliance.
• Second-Line Mechanical Devices: Vaginal pessaries (e.g., incontinence dish or ring with knob) or disposable urethral inserts support the bladder neck and compress the urethra during intra-abdominal pressure spikes.
• Surgical Gold Standard: Midurethral synthetic sling (tension-free vaginal tape [TVT] or transobturator tape [TOT]) or bladder neck suspension (Burch colposuspension). In men with post-prostatectomy stress incontinence, an artificial urinary sphincter (AUS) is the gold standard.

2. Urgency Urinary Incontinence (UUI) / Overactive Bladder (OAB)

• First-Line Behavioral Interventions: Bladder training (scheduled timed voiding with progressive interval expansion by 15-30 minutes), urge suppression techniques (deep diaphragmatic breathing, pelvic floor distraction contractions), caffeine, artificial sweetener, and alcohol reduction, and fluid moderation.
• Second-Line Pharmacotherapy:
  • Antimuscarinics / Anticholinergics (Oxybutynin, Tolterodine, Solifenacin, Fesoterodine, Darifenacin):
    • Competitively antagonize muscarinic M2 and M3 receptors in the detrusor muscle, abolishing involuntary spasms.
    • Adverse Effects: Dry mouth, severe constipation, blurred vision, dyspepsia, and urinary retention.
    • Geriatric Caution (Beers Criteria): Central anticholinergic burden causes cognitive decline, memory impairment, delirium, and is epidemiologically associated with an increased long-term risk of incident dementia. Avoid in older adults and patients with cognitive vulnerability.
  • Beta-3 Adrenergic Receptor Agonists (Mirabegron 25 to 50 mg daily, Vibegron 75 mg daily):
    • Stimulate beta-3 adrenergic receptors on the detrusor muscle, activating adenylyl cyclase to produce smooth muscle relaxation and increase functional bladder capacity during filling without blocking muscarinic receptors.
    • Major Clinical Advantage: Free of anticholinergic central nervous system adverse effects; safe for cognitive function in older adults.
    • Precautions: Mirabegron can increase systolic blood pressure (average increase 1 to 3 mmHg); contraindicated in patients with severe uncontrolled hypertension (SBP >=180 mmHg or DBP >=110 mmHg). Vibegron has minimal blood pressure effects.
• Third-Line Refractory Therapies: Intravesical OnabotulinumtoxinA (Botox) injections into the detrusor, sacral neuromodulation (InterStim), or percutaneous tibial nerve stimulation (PTNS).

3. Overflow Incontinence

• Mandatory First Step: Decompress the distended bladder via urethral catheterization or clean intermittent self-catheterization (CIC).
• Treat the Underlying Cause: Initiate alpha-blockers or schedule surgical resection (TURP) for prostatic outlet obstruction; surgically correct pelvic organ prolapse; discontinue offending anticholinergics, opioids, or tricyclic antidepressants.
• CONTRAINDICATION: Antimuscarinic drugs and beta-3 agonists are strictly contraindicated in overflow incontinence because suppressing residual detrusor contractility will precipitate complete urinary retention.

4. Functional Incontinence

• Optimize environmental mobility: Provide bedside commodes, urinal bottles, nightlights, remove throw rugs, install raised toilet seats and grab bars.
• Implement scheduled, prompted voiding protocols every 2 to 3 hours with caregiver assistance; review and deprescribe sedating psychotropics and diuretics.